ArticleFrontiers in pharmacology2022

Cost-Effectiveness of Tislelizumab Versus Docetaxel for Previously Treated Advanced Non-Small-Cell Lung Cancer in China.

Jinhong Gong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.